Related Editorial Despite the enormous progress made in the war against cancers, ovarian cancer has proved to be a tenacious foe. Progress is being made, however, as AI predictive models are being used to better target deadly ovarian cancers. Ovarian cancer is difficult to treat and lethal, with survival rates much lower than other cancers … Continue reading “NetworkNewsAudio – Predictive Oncology (NASDAQ: POAI) Subsidiary Leverages Extensive Molecular Information Platform to Accelerate New Drug Development”
Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, this morning announced that its Helomics subsidiary has begun to sequence tumor cases from its collaboration with the UPMC Magee Women’s Hospital (http://nnw.fm/4uKXL). According to the update, the Helomics and UPMC Magee partnership focuses on analyzing the genomic and … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Achieves First Milestone in Cancer Quest 2020 Project”
Related Editorial The field of precision medicine has latched upon what may well be the Holy Grail in the fight against cancer. When big data are utilized by teams of pathologists, data can be incredibly helpful, but when the right data are comprehensively analyzed by artificial intelligence (AI)-powered models, the data can be downright lifesaving. … Continue reading “NetworkNewsAudio – Predictive Oncology (NASDAQ: POAI) Leveraging Vast Database of Drug-Response, Outcome Data”
Predictive Oncology Inc. harnessing the power of artificial intelligence and its rich database of tumor data to help clinicians match cancer patients with most effective drug treatments Like Amazon’s customer dataset, POAI’s deep database of historical tumor information positions it for industry success Precision medicine is a data problem – demonstrates the huge value of … Continue reading “Predictive Oncology Inc.’s (NASDAQ: POAI) Valuable Database Offers Hope to Cancer Patients of Today and Tomorrow”
Predictive Oncology (NASDAQ: POAI), a company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced that its Skyline Medical Division completed the sale of 10 STREAMWAY(R) Systems to a major New York hospital (http://nnw.fm/B7hxg). An article discussing the company reads, “For Predictive Oncology, this announcement represents a significant financial milestone. … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Achieves Financial Milestone via Largest Single-Hospital STREAMWAY(R) System Sale”
Predictive Oncology (NASDAQ: POAI), a company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that Helomics CTO Dr. Mark Collins will speak during the scientific session of the inaugural UK 100,000 Genomes Project (“UK100K GP”) conference, and will participate in an invite-only session on the expansion of the UK100K … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Helomics Division to Present Initial Findings of UK 100,000 Genomes Project Data at Inaugural Conference”
Predictive Oncology (NASDAQ: POAI), a developer of highly adaptable assessment methods for cancer patients to help guide personalized treatments, employs its proprietary smart tumor profiling and artificial intelligence (“AI”) platform to predict tumor drug response and improve clinical outcomes for cancer patients. An article discussing the company’s activities further reads, “Last year, POAI, then known … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Utilizing Artificial Intelligence, Smart Tumor Profiling to Augment Clinical Outcomes”
Predictive Oncology (NASDAQ: POAI) is a developer of highly adaptable assessment methods for cancer patients to help guide personalized treatments. An article discussing the company reads, “As part of Predictive Oncology’s commitment to determining the best pathways for more individualized and effective cancer treatment, one of its main subsidiaries – Helomics – partnered with the … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Takes Part in Groundbreaking Genomes Project”
POAI recently announced the sale of 10 FDA-approved, CE-marked STREAMWAY Systems STREAMWAY Systems are the first truly continuous, direct-to drain fluid-disposal solutions designed specifically for medical applications The announcement is another positive indication that POAI subsidiary Skyline Medical offers tremendous qualitative, long-term potential In a significant announcement that bodes well for the company, Predictive Oncology Inc. … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Inks its Largest Single-Hospital Sale of Revolutionary STREAMWAY(R) System”
POAI is leveraging the potential of AI and smart tumor profiling to predict tumor drug response TumorGenesis is developing innovative techniques for growing tumors in laboratory settings Helomics uses vital information from patients’ own living tumors to assist oncologists in selecting the most effective treatments Predictive Oncology Inc. (NASDAQ: POAI) is harnessing the power of … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Continues to Innovate to Improve Outcomes for Cancer Patients”
